Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports

INTRODUCTION: Imatinib mesylate (Glivec(®)/Gleevec(®)) is the standard first-line therapy for the treatment of chronic myeloid leukemia due to its high hematologic, cytogenetic, and molecular response rates and favorable long-term safety profile. A copy version of imatinib is currently available in...

Descripción completa

Detalles Bibliográficos
Autores principales: Asfour, Inas A, Elshazly, Shereen A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803998/
https://www.ncbi.nlm.nih.gov/pubmed/20062598
http://dx.doi.org/10.1186/1757-1626-2-9342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803998/
https://www.ncbi.nlm.nih.gov/pubmed/20062598
http://dx.doi.org/10.1186/1757-1626-2-9342

Ejemplares similares